14,600 Shares in Kura Oncology, Inc. (NASDAQ:KURA) Acquired by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA) in the 4th quarter, Holdings Channel.com reports. The fund purchased 14,600 shares of the company’s stock, valued at approximately $127,000.

Several other hedge funds have also made changes to their positions in KURA. FMR LLC lifted its position in Kura Oncology by 26.1% during the third quarter. FMR LLC now owns 86,431 shares of the company’s stock worth $1,689,000 after buying an additional 17,913 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Kura Oncology by 270.2% in the third quarter. BNP Paribas Financial Markets now owns 15,287 shares of the company’s stock worth $299,000 after acquiring an additional 11,158 shares during the last quarter. Jane Street Group LLC grew its holdings in Kura Oncology by 36.7% in the third quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock valued at $2,464,000 after purchasing an additional 33,848 shares during the period. Barclays PLC raised its stake in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after purchasing an additional 84,563 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after buying an additional 41,535 shares during the period.

Kura Oncology Trading Up 6.2 %

KURA opened at $5.97 on Thursday. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market capitalization of $482.11 million, a PE ratio of -2.53 and a beta of 0.83. The firm’s fifty day moving average price is $7.47 and its 200 day moving average price is $11.06.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. As a group, research analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock valued at $92,307 in the last quarter. Insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

KURA has been the topic of several research analyst reports. StockNews.com raised Kura Oncology from a “hold” rating to a “buy” rating in a research note on Friday, April 4th. UBS Group reduced their target price on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $25.50.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.